Comparing the efficacy of Mirabegron in reducing urinary symptoms associated with Parkinsons disease

Comparison of treatment efficacy of Mirabegron with alpha-blockers versus Mirabegron alone in patients of Parkinsons Disease with lower urinary tract symptoms: A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/01/048770

Enrollment

210

Registered

2023-01-05

Start date

Unknown

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G20- Parkinsons disease

Interventions

Intervention1: MIRABEGRON GROUP: Medication in the form of (Behavioral therapy + Oral Mirabegron 50mg alone) will be given to patients of PARKINSONS DISEASE with lower urinary tract symptoms for 3 mon

Eligibility

Inclusion criteria

Inclusion criteria: All patients with Parkinson disease having moderate/bothersome LUTS as per IPSS questionnaire

Exclusion criteria

Exclusion criteria: 1. Montreal Cognitive Assessment score 2. Poorly controlled diabetes or poorly controlled hypertension , 3. Indwelling catheter, 4. Renal dialysis 5. Cardiac failure requiring diuretics 6. Urinary tract infection at presentation 7. Prostate or bladder cancer 8. Uncontrolled bladder outlet obstruction

Design outcomes

Primary

Measure	Time frame
Primary Outcome measures: Change in the objectively measurable parameters namely: 1. Change in day time urinary frequency 2. Change in number of nocturia episodes 3. Change in functional bladder capacity 4. Change in QmaxTimepoint: 4 weeks	—

Secondary

Measure	Time frame
Change in the 1. IPSS score 2. OABSS (Over Active Bladder Symptom Score) 3. OAB-q SF Score 4. Patient Perception of Bladder Condition (PPBC) 5. OAB family impact measure (OAB-FIM) scoreTimepoint: 4 WEEKS, 8 WEEKS AND 12 WEEKS	—

Countries

India

Contacts

Public ContactAnshuman Singh

KASTURBA MEDICAL COLLEGE, MANIPAL

dr.anshumansingh@yahoo.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026